Jaguar Animal Health Inc. (JAGX)
NASDAQ:JAGX
Want to see JAGX full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-359.1Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented meaningful strategic and clinical positives — a sizable non-dilutive upfront/licensing arrangement, manufacturing revenue upside, and compelling proof-of-concept data with 12%–37% reductions in parenteral support and a targeted NDA timeline (H1 2027) for MVID. However, these positives are balanced by near-term commercial and financial challenges: YoY revenue decline, sustained and growing operating losses (net loss to $53.6M; Non-GAAP recurring EBITDA loss $48.1M), declining Mytesi prescription volumes, and increased dependency on partner milestone payments and manufacturing revenue under the out-license. Overall, the call communicated promising development and BD catalysts that could be transformative long term but also highlighted significant short-term financial pressures and commercialization trade-offs.Company Guidance
Non-Dilutive Licensing Deal with Future Pak
Closed U.S. out-license for Mytesi and Canalevia-CA1 with $18M upfront (company reported $16M received at signing, $2M conditional), additional ~$20M in potential milestone and future payments, and roughly $3M–$4M of additional payments already received. Jaguar will continue to manufacture crofelemer and recognize manufacturing revenue; the deal provides immediate non-dilutive cash to fund rare-disease development.
Quarterly Revenue Increase Sequentially
Combined net Q4 2025 revenue of approximately $3.2M, an increase of ~5% versus Q3 2025 (~$3.1M). Full-year 2025 net revenue totaled ~$11.5M, with ~$11.2M generated by Mytesi and Canalevia-CA1.
Compelling Clinical Proof-of-Concept in Intestinal Failure
Investigator-initiated study (UAE) demonstrated reduction in parenteral support of 12%–37% (two pediatric SBS patients: 12.5%–15.6%; one MVID patient: up to 37%) with no safety issues reported. Patients treated >1 year and experienced relapse upon treatment cessation, supporting durable clinical benefit signals.
Advancing Regulatory Path and Near-Term Development Milestones
MVID placebo-controlled trial is fully enrolled with an amendment permitting treatment-only extension; target New Drug Application (NDA) for MVID in H1 2027. Company holds Orphan Designations in U.S. and EU for MVID and SBS-IF, and expects to pursue Breakthrough/PRIME designations. Company cites large addressable market for SBS (~$8B market estimate) and estimated ~12,000 U.S. SBS-IF patients (2021).
Strategic Focus on Rare-Disease Business Development
Clear corporate strategy to shift focus to late-stage crofelemer development for rare intestinal-failure indications, pursue licensing/partnerships to secure non-dilutive funding, and leverage manufacturing capability as a profit center following the Future Pak agreement.
JAGX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
JAGX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 18, 2026 | $3.92 | $3.70 | -5.61% |
Apr 07, 2026 | $14.35 | $14.33 | -0.15% |
Nov 17, 2025 | $62.30 | $63.17 | +1.40% |
Aug 14, 2025 | $90.65 | $72.45 | -20.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Jaguar Animal Health Inc. (JAGX) report earnings?
Jaguar Animal Health Inc. (JAGX) is schdueled to report earning on Aug 19, 2026, TBA (Confirmed).
What is Jaguar Animal Health Inc. (JAGX) earnings time?
Jaguar Animal Health Inc. (JAGX) earnings time is at Aug 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is JAGX EPS forecast?
Currently, no data Available